According to a phase I clinical trial (NCT02309580) which focused on the treatment of ibrutinib for relapsed or refractory T-cell non-Hodgkin lymphoma patients, and a Phase II clinical study (NCT02581930) on patients who had metastatic melanoma with highly expressed ITK, ibrutinib did not achieved satisfied therapeutic effect. This evidence concerns the gene ITK and T-cell non-Hodgkin lymphoma.